Opinion

Video

Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naïve Patients: Data From MANIFEST and MANIFEST-2

Author(s):

Andrew Kuykendall, MD,Raajit K. Rampal, MD, PhD

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, discuss how the combination of the BET inhibitor pelabresib and the JAK inhibitor ruxolitinib led to greater reductions in spleen size and symptoms compared to ruxolitinib alone in JAK inhibitor-naïve patients with intermediate- or high-risk myelofibrosis in the MANIFEST and MANIFEST-2 trials, with an acceptable safety profile, providing evidence that targeting multiple inflammatory pathways could lead to better disease control.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
The Role of the Multidisciplinary Care Team in the Diagnosis and Management of Acute Hepatic Porphyria
Video

The Role of the Multidisciplinary Care Team in the Diagnosis and Management of Acute Hepatic Porphyria

Apr 28th 2025 - Apr 29th 2026

online-activity
View More
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Apr 28th 2025 - Apr 29th 2026

online-activity
View More
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 24th 2025 - Apr 25th 2026

online-activity
View More
Related Content
Image Credit: © สุพัฒตรา แสนพลี – stock.adobe.com
April 29th 2025

ICT01 Plus Azacitidine and Venetoclax Shows Early Evidence of Antitumor Activity in AML

Chandler Park, MD, medical oncologist, Norton Cancer Institute; Ann S. LaCasce, MD, MMSc, associate professor, medicine, lymphoma specialist, Dana-Farber Cancer Institute, Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology
March 26th 2025

Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.
April 27th 2025

Five Under 5: Top Oncology Videos for the Week of 4/20

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Acute Lymphoblastic Leukemia | Image Credit: © Nittaya – stock.adobe.com
April 23rd 2025

Inati-Cel Induces High CR and MRD Negativity Rates in CD19+ R/R B-ALL

Eunice S. Wang, MD
April 22nd 2025

Mutational Sequencing Evolutions Drive Precision Medicine Approaches for AML